Clinical Trials: Melanoma

Arizona

Tucson; Arizona Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

California

Duarte; City of Hope
A Multicenter Treatment Protocol for Compassionate Use of Ipilimumab (BMS-734016) Monotherapy in Subjects with Unresctable StageIII or Stage IV Melanoma

Duarte; City of Hope
Detection of Cellular/Immune Responses to MITF in Normal Subjects and Patients with Melanoma

Duarte; City of Hope
Identification of Genes and Pathways in Tumorigenesis and Progression of Malignant Melanoma

Duarte; City of Hope
A Phase II, Open Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects with Stage III Melanoma

Los Angeles; Jonsson Comprehensive Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Los Angeles; The Angeles Clinic & Research Institute
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Los Angeles; The Angeles Clinic & Research Institute
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Orange; St. Joseph Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Connecticut

New Haven; Yale University Cancer Center
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Florida

Bay Pines; Bay Pines VA Healthcare System
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Orlando; MD Anderson Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Pensacola; Hematology Oncology Associates
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Illinois

Evanston; Evanston Northwestern Healthcare
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Joliet; Joliet Oncology/Hematology Associates, LTD
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Park Ridge; Oncology Specialists, S.C.
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Indiana

Indianapolis; Indiana University Cancer Center
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Kentucky

Louisville; University of Louisville
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Louisiana

Baton Rouge; Mary Bird Perkins Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Maine

Scarborough; Maine Center for Cancer Medicine and Blood Disorders
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Maryland

Baltimore; Weinberg Cancer Institute At Franklin Square
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Massachusetts

Boston; Dana-Farber Cancer Inst
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Minnesota

Minneapolis; University of Minnesota
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Missouri

Columbia; Ellis Fischels Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Nebraska

Lincoln; Southeast Nebraska Hematology/Oncology
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Omaha; Nebraska Methodist Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

New Hampshire

Lebanon; Dartmouth Hitchcock Medical Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

New Jersey

Montclair; Atlantic Health Research
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

New York

New York; Memorial Sloan Kettering Cancer Center
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

North Carolina

Chapel Hill; UNC School of Medicine
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Charlotte; Blumenthal Cancer Center, Carolinas Medical Center
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Greenville; Leo W. Jenkins Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Winston-Salem; Derrick L. Davis Regional Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Oregon

Portland; Providence Cancer Center Clinical Trials
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Portland; Providence Portland Medical Center
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Pennsylvania

Bethlehem; St. Luke's Cancer Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Pittsburgh; Cancer Pavilion
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

South Carolina

Greenville; Cancer Center of the Carolinas
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Texas

Dallas; Center For Oncology Research & Treatment, P.A.
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Houston; University Of Texas
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

San Antonio; San Antonio Cancer Institute
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Virginia

Abingdon; Cancer Outreach Associates
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Charlottesville; University of Virginia
Patients with Melanoma Sought for Research Study

Charlottesville; University of Virginia
Participants With Melanoma sought For research Study

Washington

Seattle; Seattle Cancer Care Alliance
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

International

Adelaide, South Australia, Australia; Medical Oncology
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Fremantle, Australia; Fremantle Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Hobart, Tasmania, Australia; Royal Hobart Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Lismore, NS, Australia; Lismore Base Hospital, Cancer Care & Haematology Unit
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Redcliffe, Australia; Redcliffe Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Waratah, Australia; Newcastle Melanoma Unit
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Wollongong, Australia; Clinical Trials
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Wooloongabba, Australia; Princess Alexandra Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Innsbruck, Austria; Universitaet Innsbruck
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Wien, Austria; Akh Wien
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Wien, Austria; Wilhelminenspital Der Stadt Wien
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Barretos, Sao Paulo, Brazil; Hospital De Cancer De Barretos
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Jau, Sao Paulo, Brazil; Fundacao Hospital Amaral Carvalho
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Porto Alegre, Rio Grande Do Sul, Brazil; Hospital Sao Lucas - Pucrs
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Porto Alegre, Rio Grande Do Sul, Brazil; Hospital De Clínicas De Porto Alegre
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Porto Alegre, Rio Grande Do Sul, Brazil; Santa Casa De Porto Alegre
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Calgary, Ab, Canada; Tom Baker Cancer Centre
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Calgary, Alberta, Canada; Tom Baker Cancer Centre
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Edmonton, Ab, Canada; Cross Cancer Institute
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Edmonton, Alberta, Canada; Cross Cancer Institute
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Halifax, Nova Scotia, Canada; QE II Health Sciences Center
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Montreal, Qc, Canada; Hopital Du Sacre-Coeur De Montreal
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Montreal, Quebec, Canada; Royal Victoria Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Quebec, Qc, Canada; Hotel Dieu De Quebec
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Sudbury, Ontario, Canada; Northeastern Ontario Regional Cancer Centre
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Weston, Ontario, Canada; Humber River Regional Hospital
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Aarhus C, Denmark; Aarhus University Hospital
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Odense C, Denmark; Odense University Hospital
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Lyon Cedex 08, France; Centre Leon Berard
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Paris, France; Hopital Saint- Louis
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Paris Cedex 13, France; Groupe Hospitalier Pitie-Salpetriere
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Vandoeuvre Les Nancy, France; Centre Alexis Vautrin
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Villejuif, France; Institut Gustave Roussy
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Frankfurt, Germany; Klinikum D. Johann Wolfgang Goethe-Universitaet
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Graz, Germany; Lkh Universitaetsklinikum Graz
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Homburg / Saar, Germany; Universitaetsklinikum Des Saarlandes
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Jena, Germany; Klinikum Der Friedrich-Schiller-Universitat Jena
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Kiel, Germany; Universitaetsklinikum Schleswig-Holstein
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Mainz, Germany; Klinikum Der Johannes Gutenberg Universitaet Mainz
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Mannheim, Germany; Universitaetsklinikum Mannheim
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Tubingen, Germany; Universitatsklinikum Tuebingen
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Wuerzburg, Germany; Universitaetsklinikum Wuerzburg
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Genove, Italy; Istituto Nazionale Per La Ricerca Sul Cancro
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Milano, Italy; Istituto Europeo Di Oncologia
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Napoli, Italy; Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Padova, Italy; Istituto Oncologico Veneto
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Siena, Italy; Policlinico Santa Maria Alle Scotte
A Randomized, Multi-Dose, Open-Label Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or IV Melanom

Brasov, Romania; Oncology Department County Hospital Brasov
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Cluj Napoca, Romania; Oncology Institute Prof. Dr. Ion Chiricuta
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Cluj Napoca, Romania; Oncology Institute Prof. Dr. Ion Chiricuta
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Hunedoara, Romania; Clinical County Hospital Alexandru Simionescu Hunedoara
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Iasi, Romania; Center of Medical Oncology
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Sibiu, Romania; Clinical County Hospital Sibiu
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma

Timisoara, Romania; Oncology- Chemotherapy Clinic
STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma